{"id":6491,"date":"2007-12-14T12:58:00","date_gmt":"2007-12-14T12:58:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=6491"},"modified":"2022-03-31T15:09:38","modified_gmt":"2022-03-31T15:09:38","slug":"current-pharmacologic-treatment-paradigms-for-inflammatory-bowel-disease-and-the-potential-role-of-granulocyte-monocyte-apheresis","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/de\/professional\/scientific-corner\/current-pharmacologic-treatment-paradigms-for-inflammatory-bowel-disease-and-the-potential-role-of-granulocyte-monocyte-apheresis\/","title":{"rendered":"Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte\/monocyte apheresis"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Schwartz+D&amp;cauthor_id=17894921\">David Schwartz<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17894921\/#affiliation-1\">1<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ferguson+JR&amp;cauthor_id=17894921\">John R Ferguson<\/a>, Curr Med Res Opin . 2007 Nov;23(11):2715-28.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><strong>Background:&nbsp;<\/strong>A broad range of pharmacologic therapies are available to treat active inflammatory bowel disease (IBD), including 5-aminosalicylate preparations, corticosteroids, and immunosuppressants (e.g., azathio prine\/6-mercaptopurine [AZA\/6-MP] or methotrexate). Although these therapies are effective, up to 60% of patients are refractory or intolerant. Biologic therapies, such as the anti-TNF agent infliximab, offer promise but are not without controversy; despite many positive reports, steroid-refractory patients are less likely than other individuals to respond to infliximab. Effective, long-term therapies that do not add to the adverse-effects burden in patients with IBD are needed. Of these, granulocyte\/monocyte apheresis (GMA) is one promising approach.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><strong>Scope:&nbsp;<\/strong>PubMed and relevant congresses databases were searched using the terms &#8218;granulocyte\/monocyte apheresis,&#8216; &#8218;GMA,&#8216; &#8218;leukocytapheresis,&#8216; &#8218;Adacolumn,&#8216; and &#8218;Cellsorba.&#8216; These studies were further selected to include only those focusing on IBD. A time frame of 2000-2006 was used.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><strong>Findings:&nbsp;<\/strong>Data from open-label trials show that patients with moderate-to-severe IBD refractory to conventional pharmacologic treatment achieved clinical response and\/or remission after treatment with GMA. Furthermore, recent small open-label trials of GMA show increased rates of induction and maintenance of response\/remission in steroid-na\u00efve IBD patients.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><strong>Conclusions:<\/strong> The remission rates seen in these open-label clinical trials of GMA are consistent with those of currently available pharmacologic therapies for IBD. However, the majority of these trials enrolled only small numbers of patients, were largely open-label, and were of limited duration. These data must be confirmed in well-controlled, large-scale clinical trials<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17894921\/\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/pubmed.ncbi.nlm.nih.gov\/17894921\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>David Schwartz&nbsp;1,&nbsp;John R Ferguson, Curr Med Res Opin . 2007 Nov;23(11):2715-28. Background:&nbsp;A broad range of pharmacologic therapies are available to treat active inflammatory bowel disease (IBD), including 5-aminosalicylate preparations, corticosteroids, and immunosuppressants (e.g., azathio prine\/6-mercaptopurine [AZA\/6-MP] or methotrexate). Although these therapies are effective, up to 60% of patients are refractory or intolerant. Biologic therapies, such [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[337,147,588,62,424,385,105,107,135],"class_list":["post-6491","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-apheresis","scientific_tags-clinical-remission","scientific_tags-clinical-response","scientific_tags-corticosteroid-naive","scientific_tags-gma","scientific_tags-granulocytapheresis","scientific_tags-granulocyte","scientific_tags-monocyte","scientific_tags-steroid-refractory"],"acf":{"sc_authors":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte\/monocyte apheresis - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-pharmacologic-treatment-paradigms-for-inflammatory-bowel-disease-and-the-potential-role-of-granulocyte-monocyte-apheresis\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte\/monocyte apheresis - Adacyte\" \/>\n<meta property=\"og:description\" content=\"David Schwartz&nbsp;1,&nbsp;John R Ferguson, Curr Med Res Opin . 2007 Nov;23(11):2715-28. Background:&nbsp;A broad range of pharmacologic therapies are available to treat active inflammatory bowel disease (IBD), including 5-aminosalicylate preparations, corticosteroids, and immunosuppressants (e.g., azathio prine\/6-mercaptopurine [AZA\/6-MP] or methotrexate). Although these therapies are effective, up to 60% of patients are refractory or intolerant. Biologic therapies, such [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-pharmacologic-treatment-paradigms-for-inflammatory-bowel-disease-and-the-potential-role-of-granulocyte-monocyte-apheresis\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-31T15:09:38+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-pharmacologic-treatment-paradigms-for-inflammatory-bowel-disease-and-the-potential-role-of-granulocyte-monocyte-apheresis\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-pharmacologic-treatment-paradigms-for-inflammatory-bowel-disease-and-the-potential-role-of-granulocyte-monocyte-apheresis\/\",\"name\":\"Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte\/monocyte apheresis - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2007-12-14T12:58:00+00:00\",\"dateModified\":\"2022-03-31T15:09:38+00:00\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-pharmacologic-treatment-paradigms-for-inflammatory-bowel-disease-and-the-potential-role-of-granulocyte-monocyte-apheresis\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte\/monocyte apheresis - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-pharmacologic-treatment-paradigms-for-inflammatory-bowel-disease-and-the-potential-role-of-granulocyte-monocyte-apheresis\/","og_locale":"de_DE","og_type":"article","og_title":"Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte\/monocyte apheresis - Adacyte","og_description":"David Schwartz&nbsp;1,&nbsp;John R Ferguson, Curr Med Res Opin . 2007 Nov;23(11):2715-28. Background:&nbsp;A broad range of pharmacologic therapies are available to treat active inflammatory bowel disease (IBD), including 5-aminosalicylate preparations, corticosteroids, and immunosuppressants (e.g., azathio prine\/6-mercaptopurine [AZA\/6-MP] or methotrexate). Although these therapies are effective, up to 60% of patients are refractory or intolerant. Biologic therapies, such [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-pharmacologic-treatment-paradigms-for-inflammatory-bowel-disease-and-the-potential-role-of-granulocyte-monocyte-apheresis\/","og_site_name":"Adacyte","article_modified_time":"2022-03-31T15:09:38+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-pharmacologic-treatment-paradigms-for-inflammatory-bowel-disease-and-the-potential-role-of-granulocyte-monocyte-apheresis\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-pharmacologic-treatment-paradigms-for-inflammatory-bowel-disease-and-the-potential-role-of-granulocyte-monocyte-apheresis\/","name":"Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte\/monocyte apheresis - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2007-12-14T12:58:00+00:00","dateModified":"2022-03-31T15:09:38+00:00","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/current-pharmacologic-treatment-paradigms-for-inflammatory-bowel-disease-and-the-potential-role-of-granulocyte-monocyte-apheresis\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner\/6491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/media?parent=6491"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific_tags?post=6491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}